Promozione per incrementare a livello nazionale lo sviluppo clinico di nuove e più efficaci strategie di bioterapia delle neoplasie maligne.


Our history


Several of the scientific results obtained during these years at pre-clinical, experimental research level have been transferred in the clinics allowing the availability and development, in addition to the conventional treatments (mainly based on chemotherapy ), of new and innovative bio- and imunotherapeutic options for cancer treatments.


Since its inception the NIBIT decided to promote and increase at the national level the development of new and more effective strategies of bio- immunotherapy of malignant tumors. In more details the aims of NIBIT are as follows:


a) a) to promote and develop the scientific and professional interactions among different research professionals from Academy, Industry, Regulatory bodies dealing with the bio- immunotherapy of cancer;
b) b) to develop innovative clinical projects based on bio- immunotherapy of cancer;
c) c) to develop interactions with patients and/or relatives in order to circulate any useful information on the disease and of new trials that may be useful for patients.

Over the years different Italian groups have become members of the NIBIT thus increasing their scientific interaction, cooperation that resulted in a high number of pre-clinical and clinical projects in the area of biotherapy of cancer. Within such context the NIBIT has thus organized annual scientific meetings in Siena. To better manage all these activities a NIBIT Foundation was then created in the year 2006.

At the moment the NIBIT has a board that includes a President, a Secretary/Treasurer and 7 members. The members Assembly includes representatives of the major Italian institutions interested in the bio- immunotherapy of tumors. NIBIT also includes working groups each dealing with a specific issue and representing the University, Scientific Institutes, Oncological Hospitals and regulatory agencies.

Aderiscono al NIBIT:
  • Istituto Nazionale per la Ricerca sul Cancro - I.R.C.C.S. (Genova)
  • Centro di Riferimento Oncologico - I.R.C.C.S. (Aviano)
  • Istituto Nazionale dei Tumori - I.R.C.C.S. (Milano)
  • Istituto Europeo di Oncologia (Milano)
  • Istituti Fisioterapici Ospedalieri "Regina Elena" - I.R.C.C.S. (Roma)
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione "G. Pascale" - I.R.C.C.S. (Napoli)
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (Meldola)
  • Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. - Ospedale Oncologico (Bari)
  • Istituto "Giannina Gaslini" - Ospedale Pediatrico I.R.C.C.S. (Genova)
  • Policlinico "San Matteo" - I.R.C.C.S. (Pavia)
  • Istituto di Ricerca e Cura del Cancro - I.R.C.C. (Candiolo)
  • I.N.R.C.A. - Istituto di Ricovero e Cura a Carattere Scientifico (Ancona)
  • Istituto Oncologico Veneto I.R.C.C.S. (Padova)
  • Fondazione San Raffaele del Monte Tabor (Milano)
  • Azienda Ospedaliera Universitaria Senese (Siena)
  • Azienda U.S.L. di Forlì
  • Azienda Ospedaliera Ospedale Niguarda Cà Granda (Milano)
  • Università degli Studi di Perugia
  • Università di Camerino
  • Università degli Studi di Torino
  • Università degli Studi di Padova
  • Università degli Studi di Messina
  • Università degli Studi di Bologna
  • Università degli Studi di Verona
  • Temple University (Philadelphia)
  • Istituto Superiore di Sanità (Roma)
  • NIBIT (Network Italiano per la Bioterapia dei Tumori) c/o AOUS - U.O.C. Immonoterapia Oncologica - Viale Bracci 16 - 53100 Siena (Italy)
    © Copyright 2012 NIBIT. All Rights Reserved.